Market Research Logo

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for ovarian cancer including molecules at various development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as route of administration and target.

Key questions answered in the report include

  • What are the gene therapy molecules in the various development stages for ovarian cancer?
  • What are the companies that are currently involved in the development of gene therapy molecules for ovarian cancer?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule.

  • Executive summary
  • Scope of report
  • Research methodology
  • Gene therapy for ovarian cancer: An insight
    • Introduction
  • Major regulatory authorities
    • US
      • Table Drug approval process by US FDA
    • Europe
    • Japan
    • Australia
    • China
  • Pipeline landscape
    • Table Pipeline landscape
    • Table Pipeline molecules by vendors
  • Comparative analysis
    • Table Pipeline molecules by numbers
    • Table Pipeline molecules by percentage
    • Mid-stage molecules (Phase II and I/II), 2017
      • Table Overview: p53 gene therapy
      • Table Clinical trials description of p53 gene
      • Table Overview: Ofranergene obadenovec
      • Table Clinical trials description of Ofranergene obadenovec
      • Table Overview: GEN-1
      • Table Clinical trials description of GEN-1
      • Table Overview: LOAd703
      • Table Clinical trials description of LOAd703
      • Table Overview: ONCOS-102
      • Table Clinical trials description of ONCOS-102
    • Early-stage molecules (Phase I), 2017
      • Table Overview: Aglatimagene besadenovec
      • Table Clinical trials description of Aglatimagene besadenovec
      • Table Overview: TBI-1301
      • Table Clinical trials description of TBI-1301
    • Inactive molecules, 2017
      • Table Overview: BC-819
      • Table Clinical trials description of BC-819
      • Table Overview: MetXia
      • Table Overview: Gene therapy for ovarian cancer
  • Indication analysis
    • Table Analysis by type of ovarian cancer
    • Table Overview of indication
  • Therapeutic assessment (RoA based)
    • Table Assessment by RoA
    • Table Segmentation of pipeline by stage and RoA
  • Therapeutic assessment (by target)
    • Table Assessment by target
  • Key companies
    • Active companies: Category and parameters
      • Table Vendor landscape
      • Table Segmentation of companies
      • Table Overview: Advantagene, 2017
      • Table Overview: CELSION, 2017
      • Table Overview: Lokon Pharma, 2017
      • Table Overview: SiBiono GeneTech, 2017
      • Table Overview: Takara Bio, 2017
      • Table Overview: Targovax, 2017
      • Table Overview: Vascular Biogencies, 2017
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report